Maurice Ivy's  Instablog

Maurice Ivy
Send Message
I am the senior partner of Ivy, Whitfield, and Associates which is a globally operating provider of business services. We develop integrated service solutions and ideas for a lasting successful business. The Group is always there to provide any help and valuable advice our client may need. We... More
My company:
Ivy, Whitfield, and Associates
  • Ivy Investment Group continues to track OREX, raises forecast 1 comment
    Nov 27, 2010 9:03 AM | about stocks: OREX
    Orexigen Therapeutics, Inc. (Orexigen) is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. Its combination product candidates targeted for obesity are Contrave which has completed Phase III clinical trials, and Empatic, which has completed Phase II clinical trials. Contrave is a combination of two drugs, bupropion and naltrexone, in a sustained release (NYSE:SR) formulation. Bupropion is a prescribed antidepressant and smoking cessation medication; naltrexone is a treatment for alcohol and opioid addiction. Empatic is a combination of bupropion SR and zonisamide SR. Zonisamide, in a release formulation, was approved in the United States for the adjunctive treatment of partial seizures, a form of epilepsy. These product candidates regulate appetite and energy expenditure through the central nervous system (NYSE:CNS).

    Drug Type: Weight Loss
    Current FDA Status: Pending Decision
    Current Drug Phase: Phase 3

    The 7 analysts offering 12-month price forecasts for Orexigen Therapeutics Inc have a median target of 12.00, with a high estimate of 14.00 and a low estimate of 8.00. The median estimate represents a +106.90% increase from the last price of 5.80.

    The current consensus among 9 polled investment analysts is to Buy stock in Orexigen Therapeutics Inc. This rating has held steady since November, when it was unchanged from a Buy rating.

    Join Ivy Investment Group to stay ahead at

    Happy Huntin',

    Maurice Ivy
    Senior Partner
    Ivy, Whitfield, and Associates, G.P.

    Disclosure: Long OREX
    Stocks: OREX
Back To Maurice Ivy's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (1)
Track new comments
  • gretel
    , contributor
    Comments (304) | Send Message
    Very little news , poor article !
    27 Nov 2010, 12:11 PM Reply Like
Full index of posts »
Latest Followers


  • OREX doubles. Ivy Investment Group called it 3 weeks ago. Join the #1 investment group at
    Dec 8, 2010
  • GS (The Goldman Sachs Group) is still a growth machine. I see it heading smoothly to $200 per share by January.
    Nov 9, 2010
  • CBIS (Cannabis Science Inc), now down to .08 cents after topping off at .26 cents a couple of weeks ago, seems to be ripe for a bounce.
    Nov 9, 2010
More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.